Syneos Health: Adding Value to Drug Discovery

With the rising number of newly discovered diseases and the need for drugs that could deal with these issues, drug research sector is on a constant growth. However, the drug discovery process is complex and critical while clinical development is more crucial with the requirement of huge resources for the best results. Here is where the contract research organizations such as Syneos Health—the only fully integrated biopharmaceutical solutions organization—form a bridge between the discovery and launch of the drug substance for manufacturers. Data research, tests, project management and trials that are run post-approval, clinical and pre-clinical are some of the major activities covered by these CROs that add value to the drug research and development.

Created by the merger of two industry leading companies—inVentiv Health and INC Research— Syneos Health is dedicated to bring together about 24,000 clinical and commercial minds with the ability to support customers across more than 110 countries. Under the leadership of Alistair Macdonald, CEO, Syneos Health is purpose-built to accelerate customer performance to address modern drug discovery market realities. Syneos Health is a blend of Contract Research Organization (CRO) and Contract Commercial Organization (CCO). “Our innovative product development model provides opportunities to drive accelerated growth across a wide range of customers, delivering deeper strategic insights and integrated expertise,” says Macdonald.

At Syneos Health, commercial and clinical solutions live under a single roof and constantly share real world insights and knowledge that leads to getting the job done better, faster and smarter to create greater success for the customers. “We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.” It is an end-to-end game changer solution— a CRO plus CCO solution that’s designed to deliver a better way to bring therapies to life.

BAM is an end-to-end concept, working across the clinical and commercial capabilities and driven by each and every one of the company’s 24,000 employees. In addition, the solution incorporates a variety of unique Syneos Health disciplines including the Trusted Process, the Syneos Health Data Lake Ecosystem, Syneos One, Real World Evidence and the team’s deep therapeutic expertise—providing a constant stream of insights focused on two critical areas including the process acceleration and patient behavior.

With the drug industry evolving faster than ever before, and so is technology. For that reason, at Syneos Health the team believe the right strategy to leverage data and technology for success is via an open, source-agnostic and highly flexible architecture. That’s what they call as Dynamic Assembly. This enables Syneos’ teams to address the nuances of each customer, trial protocols as well as product launch quickly rather than being forced to bend legacy in-house assets to a task they were not originally designed to deliver. “Accelerating therapies to market requires breaking down traditional silos and creating precise, customized and connected approaches across the product development lifecycle from clinical development through commercialization,” adds Macdonald.

Every drug discovery, research, and development need a huge data repository. The foundation of Syneos Health’s Dynamic Assembly Strategy is the Syneos Health Data Lake Ecosystem. Designed and Developed without the constraints of legacy architecture or technology, the solution features the company’s proven Syneos Health-designed data ingestion process that clearly focuses on the quality and incorporates decades of Syneos Health learnings, in addition to their best practices.

With over two decades of experience in the biopharmaceutical industry, Macdonald is the man behind Syneos Health’s success. Driven by a highly skilled, experienced and dedicated senior management team with significant knowledge of the biopharmaceutical sector, the team is passionately committed to changing the drug developments industry, and, in turn, they are creating a smarter business model. An innovative model that can constantly accelerate and improve the process of bringing therapies to market and creating success for you and the patients you serve. Syneos Health strives to combine industry focus and depth of functional expertise with strong scientific and market knowledge to tackle highly complex business and market challenges and develop actionable strategies for its clients.

Each day at Syneos Health the team get to call upon some of the industry’s most dynamic, thought-provoking colleagues. Together, they share a lofty vision – to help change the way biopharma products get to market. “We continue to execute our strategy to further penetrate large pharma, enhance our small- to a mid-sized leadership position, and accelerate full-service Commercial solutions. These strategic business initiatives underpin our Value Creation plan which we believe will generate meaningful shareholder value in the years to come,” concludes Macdonald.

Syneos Health 2024
S

Alistair Macdonald, CEO

www.syneoshealth.com

“Accelerating therapies to market requires breaking down traditional silos and creating precise, customized and connected approaches across the product development lifecycle from clinical development through commercialization”

Magazine